Madrigal Pharmaceuticals (NASDAQ:MDGL) Q1 2024 Results Conference Call May 7, 2024 8:00 AM ET
Company Participants
Tina Ventura - Chief IRO
Bill Sibold - CEO
Mardi Dier - CFO
Conference Call Participants
Yasmeen Rahimi - Piper Sandler
Eli Merle - UBS
Liisa Bayko - Evercore
Jay Olson - Oppenheimer
Ritu Baral - TD Cowen
Thomas Smith - Leerink Partners
Akash Tewari - Jefferies
Jon Wolleben - Citizens
Andrea Tan - Goldman Sachs
Operator
Good day, and thank you for standing by. Welcome to Madrigal Pharmaceuticals First Quarter 2024 Earnings Conference Call. [Operator Instructions]. As a reminder, today's conference is being recorded.
I would now like to introduce Ms. Tina Ventura, Chief Investor Relations Officer. Please go ahead.
Tina Ventura
Thank you, Lisa. Good morning, everyone, and thank you for joining us to discuss Madrigal's first quarter 2024 earnings call. We issued a press release this morning. There's also a supplementary slide deck that accompanies this webcast and that will post immediately following the call on the Investor Relations section of our website.
On the call with me today is Bill Sibold, Chief Executive Officer; and Mardi Dier, Chief Financial Officer. They'll provide prepared remarks, and then we'll take your questions. We're shooting to keep today's call to about 45 minutes. Please note we'll be making certain forward-looking statements today. We refer you to our SEC filings for a discussion of the risks that may cause actual results to differ from the forward-looking statements.
With that, I will now turn the call over to Bill.
Bill Sibold
Well, thanks, Tina. Good morning, and thanks to everyone for joining the call today. Before we begin, I wanted to take a moment to acknowledge Dr. Stephen Harrison, who passed away at the end of April. Becky and I attended his celebration of life last week. Stephen was a leader in the field and a great partner with Madrigal as our principal investigator for the MAESTRO-NASH trial. He worked closely with Becky and had the same tenacity and determination to bring Rezdiffra through clinical development and ultimately FDA approval as the first medicine approved for NASH. We're grateful for his years of dedication that advance this field and our thoughts go out to his family, friends and colleagues. I know that many of you listening to our call today know Stephen well.
I'll now move to our earnings call and an update on the business. We are off to a terrific start in 2024 and have made substantial progress against our goal to establish Madrigal as the clear leader in NASH. We achieved U.S. FDA approval on March 14, this followed the landmark publication of our Phase III trial in the New England Journal of Medicine. Following approval, our field teams were deployed and magical patient support program was up and running.